Table 1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• This phase 2 study investigates the effects of zilovertamab vedotin on participants with metastatic solid tumors.
• Demographic data and baseline characteristics were collected to assess the study population effectively.
• Participants included in the trial exhibited a range of solid tumors at various stages of metastasis.
• Results may highlight the relevance of early demographic indicators in predicting treatment outcomes.